Pradžia › Mielodisplastiniai sindromai › Kentukis
Mielodisplastiniai sindromai klinikiniai tyrimai Kentukis
5 tyrimai dėl Mielodisplastiniai sindromai ieško dalyvių vietose Kentukis.
Miestai Kentukis
Oficialus tyrimo tekstas (anglų kalba)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06577441MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Kentucky/Markey Cancer Center, Lexington
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT05564390A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Norton Cancer Institute, Louisville
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-18 · NCT07422480The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
Renkami dalyviai1/2 fazė
Iki 22 metų · Visoms lytims · Atnaujinta 2026-08-25 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Norton Cancer Institute, Louisville
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-21 · NCT06499285Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.